<DOC>
	<DOCNO>NCT00371176</DOCNO>
	<brief_summary>The primary aim project examine whether administration D-Cycloserine ( DCS ) , partial N-methyl-D-aspartate ( NMDA ) receptor agonist show facilitate fear extinction , enhance therapeutic benefit exposure-based cognitive behavioral therapy ( CBT ) OEF/OIF veteran PTSD .</brief_summary>
	<brief_title>A Placebo-Controlled Trial D-Cycloserine Exposure Therapy Combat-PTSD</brief_title>
	<detailed_description>War-zone-related posttraumatic stress disorder ( PTSD ) major psychiatric disorder include specific disable symptoms impairment interfere soldier 's ability job . There strong evidence cognitive behavior therapy ( CBT ) treat PTSD civilian , suggest prescription return veteran , approximately 40 % patient retain PTSD diagnosis ( e.g. , Foa et al. , 1999 ) drop-out rate ~25 % . It imperative develop novel evidence-based early intervention acceptable recent veteran less drain treatment resource . If CBT shorten efficacy boost cognitive enhancer likely soldier get efficacious treatment acute stress PTSD . Our aim develop program brief effective , long-term benefit veteran virtue great amenability self-management treatment adherence beyond therapy context . This study randomize , control , double-blind treatment trial compare CBT plus DCS CBT plus placebo . Participants 68 OEF/OIF veteran PTSD randomly assign CBT plus DCS CBT plus placebo . Procedures screen subject prior randomization include detailed phone screen , administration collection questionnaire , medical assessment , two baseline structure clinical interview . Following randomization , group receive identical 6 session exposure-based CBT protocol . The DCS-augmented group receive 50 mg DCS 30 minute prior four CBT session involve imaginal exposure , whereas placebo-augmented group receive placebo pill prior session . Assessment interview conduct independent evaluator occur pre-treatment , post-treatment , 3 , 6-month follow-up . Self-report measure also administer screening , throughout 6 week treatment , 3- 6- month follow . Comparison ( ) : OEF/OIF veteran PTSD treat CBT plus DCS , compare OEF/OIF veteran PTSD treat CBT plus placebo .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Stress Disorders , Traumatic</mesh_term>
	<mesh_term>Stress Disorders , Post-Traumatic</mesh_term>
	<mesh_term>Combat Disorders</mesh_term>
	<mesh_term>Cycloserine</mesh_term>
	<criteria>Male female outpatient 18 year age old serve Operation Iraqi Freedom Operation Enduring Freedom ( OIF/OEF ) primary diagnosis ( designate patient important source distress PTSD . Willingness ability comply requirement study protocol . A lifetime history : bipolar disorder schizophrenia psychosis delusional disorder obsessivecompulsive disorder organic brain syndrome cognitive dysfunction could interfere capacity engage therapy history substance alcohol dependence ( nicotine ) last 6 month otherwise unable commit refrain alcohol use acute period study participation . Patients significant suicidal ideation enact suicidal behavior within 6 month prior intake exclude study participation refer appropriate service . Patients must concurrent psychotropic medication ( e.g. , antidepressant , anxiolytic , beta blocker ) least 2 week prior initiation randomize treatment . Serious medical illness instability hospitalization may likely within next year . Patients current past history seizure Pregnant woman , lactate woman , woman childbearing potential use medically accept form contraception ( e.g. , intra uterine device , oral contraceptive , barrier device , condom foam , implant progesterone rod stabilize least 3 month ) . Any concurrent psychotherapy initiate within 3 month baseline , ongoing psychotherapy duration specifically target PTSD exclude . General supportive therapy initiate &gt; 3 month prior acceptable . Patients seizures ongoing severe cognitive impairment compromise mental status . Patients receive Isoniazid . Patients unable understand study procedure participate inform consent process . Patients history renal insufficiency ( creatinine clearance le 50 mL/min ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Cognitive Behavior Therapy</keyword>
	<keyword>Cognitive enhancer</keyword>
	<keyword>Combat Disorders</keyword>
	<keyword>D-Cycloserine</keyword>
	<keyword>Stress Disorders , Post-Traumatic</keyword>
</DOC>